Target- |
MechanismINGAP-Peptide modulators |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of intramuscular INGAP Peptide given for the first time in humans as a potential treatment for diabetes.
100 Clinical Results associated with GMP Endotherapeutics Inc
0 Patents (Medical) associated with GMP Endotherapeutics Inc
100 Deals associated with GMP Endotherapeutics Inc
100 Translational Medicine associated with GMP Endotherapeutics Inc